Device Trial Radar · NCT05814211
Clinical Trial of New Intermittent Single-use Catheter
Last checked: Nov 20, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Aug 4, 2023
Primary completion
Nov 29, 2023
Study completion Nov 29, 2023
Sponsor
- Lead sponsor
- Coloplast A/SNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-centre, open-labelled, randomised, crossover design. The total study duration for the individual subject will be approximately 4 weeks, consisting of four site visits and two 2-week test periods at home. Visits 0 and 1 can be performed on the same day. For visit 2 and 3, 2 catheterisations will be performed in a hospital setting (one HCP catheterisation and one self-catheterisation) for bladder emptying and user experience assessments. Visit 1 and 2 are followed by a home-use test period, followed by visit 3 which terminates the study.
Conditions
- Urinary Incontinence
Interventions
Investigational device - newly developed intermittent catheterDevice
Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
Comparator device #1 - SpeediCath EveDevice
During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one. Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.
Comparator device #2 - SpeediCath Compact Plus FemaleDevice
During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one. Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Residual Volume at 1st Flow-stop (Catheterisation Performed by HCP)Time frame: Tested at site visit after 14 days of device home use.
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Odense Universitetshospital
Odense, Denmark
Sanos Clinic Vejle
Vejle, Denmark
Rigshopsitalet
Copenhagen, København Ø, Denmark
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.